Trial · NCT04573751
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mortality | month 1 | Mortality rate (percent) |
| Primary | New onset or worsening acute heart failure | month 1 | The rate (percent) of patients experiencing new onset or worsening acute heart failure. Congestion characterized by dyspnea, edema, rales, jugular venous distention and need to increase diuretic doses is a hallmark of acute heart failure prompting hospitalization |
| Secondary | Thrombolysis in myocardial infarction (TIMI) 3 | hour 1 | The rate of patients (percent) who achieved TIMI 3 coronary blood flow after percutaneous coronary intervention |
| Secondary | Change in systolic/diastolic blood pressure | minute 3 | Change in systolic/diastolic blood pressure values (mmHg) before and after intracoronary verapamil/epinephrine |
| Secondary | ST segment resolution | hour 72 | Degree of ST segment resolution on ECG (mm) |
| Secondary | Troponin I release | hour 72 | Concentration of troponin I (ng/mL) |
| Secondary | LV EF | day 10 | Left ventricular ejection fraction (LV EF) (percent) |
| Secondary | Myocardial injury | day 2 | Total volume (mL) of microvascular obstruction, myocardial necrosis, edema, and hemorrhagic impregnation according to MRI data |
| Secondary | SPECT-based coronary reserve | day 7 | Coronary reserve will be measured by cardiac single photon emission computed tomography (SPECT) with technetium-99m-labeled methoxy-isobutyl isonitrile (99mТсMIBI) at rest and during pharmacological stress-test (counts) |
| Secondary | Change in heart rate values | minute 3 | Change in heart rate values (beat per minute) before and after intracoronary verapamil/epinephrine |
| Secondary | LV EDV | 10 days | Left ventricular end-diastolic volume (LV EDV) (mL) |
| Secondary | LV ESV | day 10 | Left ventricular end-systolic volume (LV ESV) (mL) |
| Secondary | LV WMSI | day 10 | Left ventricular wall motion score index (LV WMSI) (conventional units) |
| Secondary | Arrhythmias | minute 5 | Frequency of arrhythmias (atrial fibrillation, atrial flutterу, supraventricular tachycardia, premature ventricular contractions, ventricular tachycardia, conduction disorders and other heart rhythm disorders) after intracoronary administration verapamil and/or epinephrine |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04573751/registered